Primary results from the China cohort of IMpower132: Atezolizumab (atezo) plus carboplatin (carbo) or cisplatin (cis) plus pemetrexed (pem) as first-line therapy in advanced NSCLC
单位：[1]Shanghai Chest Hosp, Shanghai, Peoples R China[2]Beijing Canc Hosp, Beijing, Peoples R China[3]Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China浙江省肿瘤医院[4]China Med Univ, Hosp 1, Shenyang, Liaoning, Peoples R China[5]Guangzhou Med Univ, Hosp 1, Guangzhou, Guangdong, Peoples R China[6]Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China首都医科大学附属北京友谊医院[7]Zhejiang Univ, Hosp 1, Sch Med, Hangzhou, Zhejiang, Peoples R China浙江大学医学院附属第一医院[8]Fudan Univ, Shanghai, Peoples R China[9]F Hoffmann La Roche Ltd, Shanghai, Peoples R China[10]Genentech Inc, San Francisco, CA 94080 USA[11]Anhui Prov Hosp, Hefei, Anhui, Peoples R China
第一作者单位：[1]Shanghai Chest Hosp, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Lu S.,Fang J.,Wang Z.,et al.Primary results from the China cohort of IMpower132: Atezolizumab (atezo) plus carboplatin (carbo) or cisplatin (cis) plus pemetrexed (pem) as first-line therapy in advanced NSCLC[J].JOURNAL of THORACIC ONCOLOGY.2021,16(4):S753-S753.
APA：
Lu, S.,Fang, J.,Wang, Z.,Fan, Y.,Liu, Y....&Cao, L..(2021).Primary results from the China cohort of IMpower132: Atezolizumab (atezo) plus carboplatin (carbo) or cisplatin (cis) plus pemetrexed (pem) as first-line therapy in advanced NSCLC.JOURNAL of THORACIC ONCOLOGY,16,(4)
MLA：
Lu, S.,et al."Primary results from the China cohort of IMpower132: Atezolizumab (atezo) plus carboplatin (carbo) or cisplatin (cis) plus pemetrexed (pem) as first-line therapy in advanced NSCLC".JOURNAL of THORACIC ONCOLOGY 16..4(2021):S753-S753
医学